Experienced in Arteriovenous Malformation

Dr. Kelly B. Pendergrass

Hematology Oncology
4881 Ne Goodview Cir, 
Lees Summit, MO 
Experienced in Arteriovenous Malformation
4881 Ne Goodview Cir, 
Lees Summit, MO 
OverviewInsuranceLocationsClinical Research

Overview

Kelly Pendergrass is a Hematologist Oncology provider in Lees Summit, Missouri. Dr. Pendergrass is rated as an Experienced provider by MediFind in the treatment of Arteriovenous Malformation. His top areas of expertise are Hemoglobin SC Disease, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Paget Disease of the Breast.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in KS
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

4881 Ne Goodview Cir, Lees Summit, MO 64064

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

7 Total Publications

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.
Journal: Breast (Edinburgh, Scotland)
Published: September 18, 2017

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pendergrass's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 76 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile